 In 1989 the United States Food and Drug Administration (FDA) approved it for use the treatment of prostate cancer.In 1995, bicalutamide was approved, and nilutamide followed a year later.The AR belongs to the steroid receptor subfamily of the nuclear receptor superfamily.